{‘She has little expertise’: the US scientific establishment braces for Dr. Høeg's role at the Food and Drug Administration.

While America continues making unprecedented changes to its immunization schedules, one figure appears unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccines throughout the pandemic and has zeroed in on possible deaths after Covid vaccination in her brief time at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Program

Public health authorities had intended to announce radical changes to the childhood immunization program recently, synchronizing the US with the Danish vaccine program, according to reports – a significant shift that would place the US out of step with much of the global community with no evidence for public health gain. The announcement has been pushed back until the next year.

In place of the director of the vaccine center, Høeg is set to address the audience at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to run the office this calendar year.

A New Direction at the Agency

The acting appointment could signify a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Prasad solidify control at the FDA – and it points to a renewed priority upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for discontinuing certain pediatric shot schedules in the US in order to be more similar to Denmark's approach, a country with nationalized medicine and a population about the population of Wisconsin’s.

To date public appearances, she has continued to focus on vaccination policy – traditionally the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Questions Over Expertise

Høeg has no obvious experience in pharmaceutical research, regulation or administrative roles, which has been customary for previous heads of the CBER. She has worked at the FDA as a top consultant to the FDA chief and CBER since spring.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She lacks experience in leading a major agency. She has no expertise in industry regulation.”

Previous directors of CBER would “grasp laws and regulations and the underlying principles of medication creation”, commented Janet Woodcock. “Frankly, she doesn’t have the sort of resume that former directors who ran the center have had.”

The drug center has an immense range of responsibilities at the FDA, Woodcock pointed out.

“The public just focuses on the innovative therapies, but the off-patent medication office approves numerous generic medications. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these must be managed,” she explained. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a major leadership element to the role, which manages over 5,000 personnel. “It’s a huge administrative position, if you execute it properly,” Woodcock concluded.

Official Statement and Controversial Programs

Regarding inquiries about Dr. Høeg's credentials and whether this assignment signifies more teamwork among agency officials on vaccines, a press secretary responded that the “concerns are based on flawed presumptions”.

“This background aligns with the functions of her role,” the representative stated, pointing to the months Høeg spent advising the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a contentious rapid drug-approval program that reportedly concerned her predecessors. “How are these therapies being chosen for this fast-track system? Who takes the decisions?” Howard said. “There is a lot of lack of transparency happening at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration appears to be shifting towards less stringent regulations of all drugs, with the exception of shots.”

Established Track Record on Immunizations

With immunizations, Dr. Høeg has a more established, if troubling, past, some experts have noted. She authored a research paper using unverified crowd-sourced reports to assess the rate of heart inflammation after Covid immunization. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the incoming administration encompassed revising regulations for novel immunizations and discontinuing “non-essential” vaccines, she stated following the vote on a audio program. At the FDA, Dr. Høeg has allegedly proposed excluding young men from obtaining COVID-19 vaccinations.

“She’s an all-around ideologue who begins with her preconceived notions and works backwards to fit the data in a highly misleading, untruthful fashion,” Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of other skeptics, {like|